Read our Health industries quarterly insights for accounting and reporting updates impacting health services, pharma, life sciences, and medtech. This edition includes insights into real-world evidence and its impacts on the pharma value chain, generative AI and the risks posed to organizations, SEC comment letter trends, amendments to SEC rules on share repurchase disclosures, accounting standard-setting updates, and more.
Spotlight: Real-world evidence comes of age for pharma
Understanding how medicines perform in the real world has the potential to transform the pharma business — from driving increased efficiency and cost savings in drug development, to helping identify new patient populations for marketed drugs. The rapid expansion of the real-world evidence (RWE) ecosystem is broadening what is achievable with real-world data while simultaneously increasing the complexity, investment and experience required for successful deployment across the value chain.
Via PwC